ECTRIMS-ACTRIMS 2023: Ozanimod Aids Cognitive Impairment at One Year With Early Relapsing Multiple Sclerosis
Additionally, at one year, MRI lesion counts were reduced with no new safety concerns
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.